DAFNA Capital Management’s Spero Therapeutics SPRO Stock Holding History

DAFNA Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-125,000	Closed	-$90K	–	81
2025 Q1	$90K	Hold	125,000	–	–	0.03%	82
2024 Q4	$129K	Hold	125,000	–	–	0.03%	82
2024 Q3	$168K	Hold	125,000	–	–	0.04%	83
2024 Q2	$163K	Hold	125,000	–	–	0.04%	82
2024 Q1	$215K	Hold	125,000	–	–	0.05%	71
2023 Q4	$184K	Hold	125,000	–	–	0.04%	71
2023 Q3	$151K	Hold	125,000	–	–	0.05%	72
2023 Q2	$181K	Hold	125,000	–	–	0.05%	72
2023 Q1	$181K	Hold	125,000	–	–	0.05%	70
2022 Q4	$216K	Hold	125,000	–	–	0.06%	73
2022 Q3	$250K	Buy	+125,000	New	+$124K	0.07%	83
2020 Q4	–	Sell	-100,000	Closed	-$1.12M	–	83
2020 Q3	$1.12M	Buy	+100,000	New	+$1.18M	0.36%	55
2020 Q2	–	Sell	-48,103	Closed	-$389K	–	91
2020 Q1	$389K	Buy	+48,103	New	+$424K	0.16%	70
2019 Q4	–	Sell	-39,395	Closed	-$418K	–	86
2019 Q3	$418K	Sell	39,395 -30,605	-44%	-$323K	0.16%	74
2019 Q2	$806K	Hold	70,000	–	–	0.3%	62
2019 Q1	$897K	Hold	70,000	–	–	0.39%	55
2018 Q4	$431K	Hold	70,000	–	–	0.21%	59
2018 Q3	$736K	Buy	+70,000	New	+$812K	0.3%	56
2018 Q2	–	Sell	-29,544	Closed	-$421K	–	83
2018 Q1	$421K	Buy	29,544 +24,544	+491%	+$298K	0.2%	62
2017 Q4	$59K	Buy	+5,000	New	+$61.4K	0.03%	72

Other funds holding SPRO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

DAFNA Capital Management's SPRO Position: Q2 2025 in Review

DAFNA Capital Management sold out of Spero Therapeutics (SPRO) in Q2 2025, closing a stake of 125,000 shares — an estimated $90K sold.

DAFNA Capital Management first reported a position in SPRO in Q4 2017 and held it in 20 quarters. The position peaked at $1.12M in Q3 2020. 44 funds tracked by Wall St. Rank hold SPRO as of Q2 2025.

DAFNA Capital Management reported no remaining Spero Therapeutics position as of Q2 2025 after selling out during the quarter.
DAFNA Capital Management sold 125,000 Spero Therapeutics shares in Q2 2025, an estimated $90K.
DAFNA Capital Management first reported a position in Spero Therapeutics in Q4 2017 and held it in 20 quarters.
DAFNA Capital Management's Spero Therapeutics position peaked at $1.12M in Q3 2020.
44 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2025.

Based on DAFNA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.